Researcher
Patrick Schöffski
- Disciplines:Laboratory medicine, Palliative care and end-of-life care, Regenerative medicine, Other basic sciences, Other health sciences, Nursing, Other paramedical sciences, Other translational sciences, Other medical and health sciences
Affiliations
- Laboratory of Experimental Oncology (Division)
Responsible
From1 Jan 2012 → Today - Laboratory of Experimental Oncology (Division)
Member
From1 Oct 2005 → Today
Projects
1 - 10 of 12
- Real-time qPCR platform enhancing research activities within the Laboratory of Experimental Oncology and the Laboratory of Experimental RadiotherapyFrom1 Jan 2023 → TodayFunding: BOF - scientific equipment program
- PhD student in preclinical research on sarcoma treatmentFrom3 Oct 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Preclinical evaluation of innovative cytotoxic drugs for the treatment of soft tissue sarcomaFrom28 Oct 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Whole-genome optical mapping for comprehensive analysis of sarcoma genomes in a diagnostic settingFrom13 Oct 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Exploring the biology of translocation-related sarcomas and impact on the research for new therapy options.From1 Oct 2020 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- CYTOTOXIC THERAPY REVISED: EXPLORATION OF INNOVATIVE (PRO)DRUGS IN PATIENT-DERIVED XENOGRAFTS OF SOFT TISSUE SARCOMAFrom1 Sep 2018 → 25 Oct 2022Funding: Own budget, for example: patrimony, inscription fees, gifts
- Molecular characterization of soft tissue sarcoma and the potential clinical applicationsFrom26 Sep 2017 → 25 Feb 2022Funding: Own budget, for example: patrimony, inscription fees, gifts
- Clinical outcome, Pathological results and immunohistochemical findings of rare subtypes of soft tissue sarcomasFrom10 Aug 2015 → 30 Sep 2017Funding: Nonprofit institution or equivalents
- Establishment of new research models and in vivo efficacy testing of novel treatment strategies for resistant gastrointestinal stromal tumorsFrom1 Aug 2014 → 19 May 2017Funding: Own budget, for example: patrimony, inscription fees, gifts
- Targeting soft tissue sarcoma with smart molecules - exploring cytotoxic prodrugs and target-specific inhibitors in patient-derived xenograftsFrom1 Aug 2013 → 30 Nov 2017Funding: Nonprofit institution or equivalents
Publications
41 - 50 of 382
- Brightline-1: phase II/III trial of the MDM2-p53 antagonist BI 907828 versus doxorubicin in patients with advanced DDLPS(2022)
Authors: Patrick Schöffski
Pages: 621 - 629 - Molecular characterization of soft tissue sarcoma and the potential clinical applications(2022)
Authors: Jerry Lee, Patrick Schöffski, Agnieszka Wozniak
- Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies(2022)
Authors: Patrick Schöffski
- Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma(2022)
Authors: Patrick Schöffski
Pages: 127 - + - Case Report: An Unusual Course of Angiosarcoma After Lung Transplantation(2022)
Authors: Lucienne Michaux, Isabelle Vanden Bempt, Sascha Vermeer, Patrick Schöffski, Birgit Weynand, Raf Sciot, Laurens Ceulemans, Laurent Godinas, Geert Verleden, Dirk Van Raemdonck, et al.
- Overall survival improvement in patients with metastatic clear-cell renal cell carcinoma between 2000 and 2020: a retrospective cohort study(2022)
Authors: Annouschka Laenen, Marcella Baldewijns, Herlinde Dumez, Paul Clement, Hans Wildiers, Patrick Schöffski, Eduard Roussel, Lisa Kinget, Maarten Albersen, Benoit Beuselinck
Pages: 22 - 29 - Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up(2022)
Authors: Eric Legius, Patrick Schöffski
Pages: 20 - 33 - Comprehensive Molecular Analysis of Inflammatory Myofibroblastic Tumors Reveals Diverse Genomic Landscape and Potential Predictive Markers for Response to Crizotinib(2021)
Authors: Jerry Lee, Patrick Schöffski, Elodie Modave, Bram Boeckx, Maria Debiec-Rychter, Raf Sciot, Diether Lambrechts, Agnieszka Wozniak
Pages: 6737 - 6748 - Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study(2021)
Authors: Patrick Schöffski
Pages: 6333 - 6342 - Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up(2021)
Authors: Eric Legius, Patrick Schöffski
Pages: 1520 - 1536